Fundraising FoxM Ventures — 2025 Investments
9 investments dated 2025 · listed companies and verified rows first · show all
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsHadean VenturesInnovestor VenturesSofinnova Partners4BIO CapitalBioqube Ventures
ChemPower develops an abrasive-free chemical mechanical planarization (CMP) technology and materials for advanced semiconductor chip manufacturing.
Advanced ManufacturingCleantechNew MaterialsSemiconductorsBeaverton, US
Sudhanshu Misra(CEO)inSV Babu(CTO)
BoardSCOTT SHAW(Director)inOWEN LOZMAN(Director)JESSICA FREYER(Director)inBABU SURYADEVARA(Director)
Co-investorsFoothill VenturesIn-Q-TelIntel CapitalPangaea Ventures Us Inc.Portland Seed FundRhapsody Venture Partners+3 more
Mosa Meat is a company developing cultivated meat.
BiotechClimate TechFoodTech
Mark Post(Founder)Mark W. Post(Founder)Peter Verstrate(Founder)
Co-investorsAgronomicsArcTern VenturesBlue Horizon CorporationCollateral GoodLowercarbon CapitalMbuyu Capital Partners+8 more
NovoLINC develops nanocomposite thermal interface materials designed to lower thermal resistance and improve heat dissipation in electronic chipsets.
Deep TechHardwareNew MaterialsPittsburgh, US
Robert Wenner(Executive Officer)Sheng Shen(Executive Officer, Director)
BoardTina Tosukhowong(Director)inEric Rosenblum(Director)inNing Li(Executive Officer, Director)inPaul Sheng(Director)in
Co-investorsFoothill VenturesHitachi VenturesTDK VenturesCarnegie Mellon UniversityFathom Fund
.jpeg){kind=logo}
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankDementia Discovery FundOmega Funds
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoinMichael Martin(President, Chief Executive Officer)inStephen Mullennix(Executive Officer)inSerge Messerlian, M.Sc., M.B.A.(Chief Executive Officer)
BoardSerge Messerlian(Director)in
Co-investorsaMoonCRV (Charles River Ventures)DCVC (Data Collective)Neotribe VenturesPivotal Life SciencesSoftBank Vision Fund+3 more
ReproNovo develops therapeutic solutions for male and female fertility and women's health conditions like adenomyosis, targeting unmet medical needs in reproductive medicine.
BiotechFemTechHealthtechMedical DevicesLausanne, CH
Co-investorsJeito CapitalYsios Capital
TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.
BiotechDeep TechLongevityMedical DevicesCambridge, GB
Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)
Co-investorsCambridge Innovation CapitalPfizer VenturesSV Health InvestorsPfizer Venture InvestmentsStart CodonDiamond Edge Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.